COMMENTARY: Mortality rate from early prostate cancer increased 3-fold after 15 years following the diagnosis

Barry, Michael J.
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p24
Academic Journal
The article reports that mortality rate from early prostate cancer increased three-fold after 15 years following the diagnosis. For the minority of men diagnosed with poorly differentiated cancer or with rapidly rising prostate-specific antigen (PSA) levels, it is unclear whether such local treatments as radical prostatectomy or radiation can change outcomes. Most prostate cancer guidelines suggest reserving PSA testing and attempted curative treatment for men with 10 years of life expectancy or about 75 years of age for men with average comorbid conditions.


Related Articles

  • Intermittent ADT may benefit men with advanced PCa. Sieve, Vonne // Urology Times;4/1/2006, Vol. 34 Issue 4, p16 

    The article reveals that intermittent androgen suppression is beneficial in select men with advanced prostate cancer. Intermittent therapy is generally defined as administration of total androgenic blockade until the prostate-specific antigen falls to zero or near zero. The article discusses...

  • Utilità della linfoadenectomia pelvica nel carcinoma prostatico con PSA <10 ng/ml. BERARDI, B.; PICCINNI, R.; CAFARELLI, A.; CALLEA, A.; TEMPESTA, A.; GALA, F.; ZIZZI, V.; SBLENDORIO, D.; CRUDELE, G.; TRAFICANTE, A. // Urologia;2009 Supplement, Vol. 76 Issue S-12, pS41 

    Radical prostatectomy is the best treatment for patients with T1-2 prostate cancer and a life expectancy of over 10 years, but no pN1 patient that underwent only surgery, was progression free at 10 years (Partin 1994). In the last 10 years we performed 441 consecutive pelvic lymphadenectomy in...

  • Prostate Cancer: Monitor or Treat?  // HEALTHWire Senior Health Topics;Jan2017, p1 

    The article reports on an increase in number of patients with prostate cancer in the U.S. found by Prostate Testing for Cancer and Treatment (ProtecT) trial. Topics discussed include using Prostate-Specific Antigen (PSA) test followed by a biopsy to diagnose early stage prostate, side effects of...

  • Screening for Prostate Cancer Risk: Fantasy or Reality. Batra, Jyotsna; Yousef, George M. // Canadian Journal of Pathology;Winter2015, Vol. 7 Issue 4, p4 

    No abstract available.

  • Data Support Intermittent Androgen Suppression.  // Renal & Urology News;Apr2011, Vol. 10 Issue 4, p24 

    The article reports on the outcomes associated with intermittent androgen suppression (IAS) and continuous androgen deprivation (CAD) when applied to men who have prostate-specific antigen (PSA) progression after radiotherapy for prostate cancer (PCa).

  • RP has edge over radiotherapy in low-risk patients. Guttman, Cheryl // Urology Times;Sep2002, Vol. 30 Issue 9, p13 

    Compares the efficacy of radical prostatectomy versus external beam radiation therapy for treating clinically localized prostate cancer diagnosed during prostate-specific antigen (PSA) screening. Survival rate; Radiation dose; Link of radiation dose and PSA outcome.

  • Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).  // Current Medical Literature: Urology;2008, Vol. 14 Issue 3, p65 

    The article discusses research on the use of prostate-specific antigen (PSA) level to guide the optimum timing of androgen-deprivation therapy (ADT) in prostate cancer. It references a study by U. E. Studer et al, published in volume 53 of "European Urology." They found that patients with a PSA...

  • Prostate Cancer and Pomegranate Juice. Finkel, Jon // Life Extension;Oct2009, Vol. 15 Issue 10, p1 

    The article presents findings of a study which examines the effect of pomegranate juice on men who underwent radiation therapy or surgery for prostate cancer in the U.S. The study revealed that lower prostate-specific antigen (PSA) levels were found in men who take eight ounces of pomegranate...

  • Does the Benefit Justify the Risk? Albertsen, Peter C. // JNCI: Journal of the National Cancer Institute;1/6/2010, Vol. 102 Issue 1, p4 

    The article discusses various issues concerning the clinical use and adverse outcomes of androgen deprivation therapy (ADT). A brief historical perspective on prostate-specific antigen (PSA) and ADT is presented. The adverse outcomes of ADT are described, including its negative effect on quality...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics